Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
25 studies found for:    cG250
Show Display Options
Rank Status Study
1 Completed Study of Lutetium-177 Labeled cG250 in Patients With Advanced Renal Cancer
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: 111-In-DOTA-cG250;   Drug: 177-Lu-DOTA-cG250
2 Terminated Study of Safety and Effects of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Biological: Chimeric monoclonal antibody cG250;   Drug: Sunitinib malate
3 Completed Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Sorafenib;   Drug: 111Indium-bevacizumab;   Drug: 111Indium-cG250
4 Completed Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Conditions: Cancer of Kidney;   Kidney Cancer;   Renal Cancer;   Neoplasms, Kidney;   Renal Neoplasms
Intervention: Drug: 124-Iodine-cG250 (124I-cG250)
5 Completed
Has Results
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Conditions: Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: 124-Iodine-cG250 (124I-cG250);   Procedure: CT
6 Recruiting Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Condition: Renal Cancer
Intervention: Drug: 124IcG250
7 Unknown  Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250
Conditions: Renal Cell Carcinoma;   Kidney Neoplasm;   Renal Cancer;   Kidney Cancer
Intervention: Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)
8 Completed Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: girentuximab;   Other: placebo
9 Completed Brivanib Metastatic Renal Cell Carcinoma
Condition: Male and Female Subjects 18 Years of Age and Older With Metastatic Renal Cell Carcinoma. Eligible Patients Must Have Undergone and Failed Prior Treatment.
Interventions: Drug: Brivanib alaninate;   Genetic: Polymerase chain reaction;   Other: Iodine I 124 chimeric monoclonal antibody G250;   Procedure: Positron emission tomography/computed tomography;   Genetic: Protein expression analysis;   Other: Immunohistochemistry
10 Completed Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Condition: Kidney Cancer
Intervention: Radiation: iodine I 131 chimeric monoclonal antibody G-250
11 Recruiting Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
Condition: Metastatic Clear Cell Renal Cell Carcinoma
Intervention: Drug: Lu-177-DOTA-girentuximab
12 Not yet recruiting REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
Conditions: Renal Cell Carcinoma;   Kidney Cancer
Intervention: Drug: Iodine (124I) Girentuximab
13 Completed
Has Results
A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Conditions: Pain;   Knee Osteoarthritis
Interventions: Drug: Tapentadol ER (100 to 250 mg twice daily);   Drug: Matching Placebo (twice daily);   Drug: Oxycodone  CR (20 to 50 mg twice daily)
14 Completed
Has Results
A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
Conditions: Osteoarthritis, Hip;   Osteoarthritis, Knee;   Lower Back Pain;   Pain
Interventions: Drug: Oxycodone CR;   Drug: Tapentadol (CG5503) ER
15 Completed
Has Results
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
Conditions: Pain;   Osteoarthritis;   Low Back Pain
Intervention: Drug: Tapentadol (CG5503) Extended Release (ER)
16 Completed
Has Results
Tapentadol (CG5503)
Conditions: Osteoarthritis, Knee;   Pain
Interventions: Drug: oxycodone;   Drug: placebo;   Drug: tapentadol (CG5503)
17 Completed
Has Results
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Drug: tapentadol (CG5503) ER;   Drug: oxycodone CR;   Drug: placebo
18 Completed
Has Results
Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Drug: tapentadol (CG5503) Immediate Release IR;   Drug: tapentadol (CG5503) Extended Release (ER);   Drug: tapentadol (CG5503) Immediate Release (IR)
19 Completed
Has Results
A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine
Conditions: Tumor;   Pain
Interventions: Drug: Tapentadol Extended Release;   Drug: Matching Placebo after Tapentadol in the Titration Phase.;   Drug: Morphine Sulphate Controlled Release
20 Completed
Has Results
A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy
Condition: Diabetic Neuropathy
Interventions: Drug: CG5503;   Drug: placebo

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Indicates status has not been verified in more than two years